Literature DB >> 27199372

DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.

Sarah Klein1, Lothar C Dieterich1, Anthony Mathelier2, Chloé Chong1, Adriana Sliwa-Primorac1, Young-Kwon Hong3, Jay W Shin4, Marina Lizio4, Masayoshi Itoh4, Hideya Kawaji4, Timo Lassmann5, Carsten O Daub4, Erik Arner4, Piero Carninci4, Yoshihide Hayashizaki6, Alistair R R Forrest7, Wyeth W Wasserman2, Michael Detmar8.   

Abstract

Lymphangiogenesis plays a crucial role during development, in cancer metastasis and in inflammation. Activation of VEGFR-3 (also known as FLT4) by VEGF-C is one of the main drivers of lymphangiogenesis, but the transcriptional events downstream of VEGFR-3 activation are largely unknown. Recently, we identified a wave of immediate early transcription factors that are upregulated in human lymphatic endothelial cells (LECs) within the first 30 to 80 min after VEGFR-3 activation. Expression of these transcription factors must be regulated by additional pre-existing transcription factors that are rapidly activated by VEGFR-3 signaling. Using transcription factor activity analysis, we identified the homeobox transcription factor HOXD10 to be specifically activated at early time points after VEGFR-3 stimulation, and to regulate expression of immediate early transcription factors, including NR4A1. Gain- and loss-of-function studies revealed that HOXD10 is involved in LECs migration and formation of cord-like structures. Furthermore, HOXD10 regulates expression of VE-cadherin, claudin-5 and NOS3 (also known as e-NOS), and promotes lymphatic endothelial permeability. Taken together, these results reveal an important and unanticipated role of HOXD10 in the regulation of VEGFR-3 signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability.
© 2016. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  HOXD10; Immediate early gene; Lymphangiogenesis; Lymphatic endothelium; Transcription factor; VEGFR-3

Mesh:

Substances:

Year:  2016        PMID: 27199372     DOI: 10.1242/jcs.186767

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  5 in total

1.  Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways.

Authors:  Gabriele Bonetti; Stefano Paolacci; Michele Samaja; Paolo Enrico Maltese; Sandro Michelini; Serena Michelini; Silvia Michelini; Maurizio Ricci; Marina Cestari; Astrit Dautaj; Maria Chiara Medori; Matteo Bertelli
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

2.  Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP.

Authors:  Tomokazu Souma; Benjamin R Thomson; Stefan Heinen; Isabel Anna Carota; Shinji Yamaguchi; Tuncer Onay; Pan Liu; Asish K Ghosh; Chengjin Li; Vera Eremina; Young-Kwon Hong; Aris N Economides; Dietmar Vestweber; Kevin G Peters; Jing Jin; Susan E Quaggin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-22       Impact factor: 11.205

3.  Lymphatic MAFB regulates vascular patterning during developmental and pathological lymphangiogenesis.

Authors:  Lothar C Dieterich; Carlotta Tacconi; Franziska Menzi; Steven T Proulx; Kübra Kapaklikaya; Michito Hamada; Satoru Takahashi; Michael Detmar
Journal:  Angiogenesis       Date:  2020-04-19       Impact factor: 9.596

4.  Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation.

Authors:  Lothar C Dieterich; Luca Ducoli; Jay W Shin; Michael Detmar
Journal:  Sci Data       Date:  2017-08-29       Impact factor: 6.444

5.  A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure.

Authors:  Guorong Li; Astrid F Nottebaum; Mitchell Brigell; Iris D Navarro; Ute Ipe; Sarthak Mishra; Maria Gomez-Caraballo; Heather Schmitt; Brandi Soldo; Steve Pakola; Barbara Withers; Kevin G Peters; Dietmar Vestweber; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.